Τίτλος:
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Patients with moderate to severe hidradenitis suppurativa failing adalimumab therapy, or those ineligible to receive it, remain a population with an unmet need. Twenty patients not eligible for adalimumab were randomized to receive 12 weeks of blind treatment with placebo or MABp1, a true human antibody targeting IL-1α. Hidradenitis suppurativa clinical response score at week 12 was the primary endpoint. The primary endpoint was met in 10% and 60% of placebo- and MABp1-treated patients, respectively (odds ratio = 13.50, 95% confidence interval = 1.19–152.51). Clinical efficacy was maintained at 24 weeks in 0% and 40%. Improvement in the visual analog scale was reported by 20% and 85.7%, respectively, of patients failing previous anti-TNF treatment. Ultrasonography showed decreased neovascularization and lesion skin depth in the MABp1 group. MABp1 treatment was associated with decrease of circulating IL-8 and of stimulated production of IL-8 by whole blood. Whole blood production for hBD-2 was negatively associated with changes on ultrasonography in the placebo group but not in the MABp1 group. MABp1 is a promising treatment for patients with hidradenitis suppurativa not eligible for adalimumab. Inhibition of neovascularization and modulation of the production of IL-8 and hBD-2 are suggested mechanisms of action. © 2017 The Authors
Συγγραφείς:
Kanni, T.
Argyropoulou, M.
Spyridopoulos, T.
Pistiki, A.
Stecher, M.
Dinarello, C.A.
Simard, J.
Giamarellos-Bourboulis, E.J.
Περιοδικό:
Journal of Investigative Dermatology
Λέξεις-κλειδιά:
adalimumab; interleukin 1; interleukin 8; monoclonal antibody; monoclonal antibody p1; placebo; tumor necrosis factor inhibitor; unclassified drug; adalimumab; IL1A protein, human; interleukin 1alpha; MABp1 monoclonal antibody; monoclonal antibody; tumor necrosis factor, adult; Article; clinical article; controlled study; cytokine production; Dermatology Life Quality Index; disease activity; disease exacerbation; disease severity; double blind procedure; drug efficacy; drug mechanism; drug targeting; drug treatment failure; echography; follow up; Hidradenitis Suppurativa Clinical Response score; hospitalization; human; immunomodulation; modified Sartorious score; neovascularization (pathology); patient-reported outcome; Physician Global Assessment; priority journal; prospective study; randomized controlled trial; scoring system; skin defect; suppurative hidradenitis; treatment duration; treatment response; visual analog scale; antagonists and inhibitors; blood; female; immunology; male; middle aged; prognosis; retrospective study; severity of illness index; suppurative hidradenitis; time factor; treatment failure, Adalimumab; Antibodies, Monoclonal; Female; Follow-Up Studies; Hidradenitis Suppurativa; Humans; Interleukin-1alpha; Male; Middle Aged; Prognosis; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Failure; Tumor Necrosis Factor-alpha; Ultrasonography
DOI:
10.1016/j.jid.2017.10.030
